ACR 2022 Tweet by Olga Petryna
Tweet
Related Content
Podcast
Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could change how you practice dermatology. I'm Jack Cush from RheumNow, and This is Derm on RheumNow.
This month’s podcast will Scratch the surface and…
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors.Features Dr. Jack Cush, Editor at RheumNow.com.Show Notes:FDA Grants Priority Review…
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA &…
